JP2002544234A - 発作の処置のための骨髄移植 - Google Patents

発作の処置のための骨髄移植

Info

Publication number
JP2002544234A
JP2002544234A JP2000617907A JP2000617907A JP2002544234A JP 2002544234 A JP2002544234 A JP 2002544234A JP 2000617907 A JP2000617907 A JP 2000617907A JP 2000617907 A JP2000617907 A JP 2000617907A JP 2002544234 A JP2002544234 A JP 2002544234A
Authority
JP
Japan
Prior art keywords
cells
bone marrow
brain
spinal cord
mscs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000617907A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002544234A5 (enExample
Inventor
イ リ，
マイケル チョップ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Henry Ford Health System
Original Assignee
Henry Ford Health System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henry Ford Health System filed Critical Henry Ford Health System
Publication of JP2002544234A publication Critical patent/JP2002544234A/ja
Publication of JP2002544234A5 publication Critical patent/JP2002544234A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
JP2000617907A 1999-05-14 2000-05-11 発作の処置のための骨髄移植 Pending JP2002544234A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13434499P 1999-05-14 1999-05-14
US60/134,344 1999-05-14
PCT/US2000/012875 WO2000069448A1 (en) 1999-05-14 2000-05-11 Bone marrow transplantation for treatment of stroke

Publications (2)

Publication Number Publication Date
JP2002544234A true JP2002544234A (ja) 2002-12-24
JP2002544234A5 JP2002544234A5 (enExample) 2010-09-16

Family

ID=22462927

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000617907A Pending JP2002544234A (ja) 1999-05-14 2000-05-11 発作の処置のための骨髄移植

Country Status (9)

Country Link
US (1) US20090162327A1 (enExample)
EP (1) EP1183035B1 (enExample)
JP (1) JP2002544234A (enExample)
AU (1) AU780994B2 (enExample)
CA (1) CA2373808C (enExample)
DK (1) DK1183035T3 (enExample)
ES (1) ES2531592T3 (enExample)
PT (1) PT1183035E (enExample)
WO (1) WO2000069448A1 (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005007176A1 (ja) * 2003-06-27 2005-01-27 Renomedix Institute Inc. 間葉系細胞を有効成分とする体内投与用脳神経疾患治療薬
JP2008063323A (ja) * 2006-09-06 2008-03-21 Henrich Cheng 損傷神経修復のためのフィブリン接着組成物およびその方法
JP2009067685A (ja) * 2007-09-10 2009-04-02 St Marianna Univ School Of Medicine 中枢神経再生剤
JP2011513318A (ja) * 2008-02-28 2011-04-28 ヘンリ フオルド ヘルス システム 中枢神経系損傷の治療を強化するために間質細胞を使用する組成物及び方法
US7968088B2 (en) 2003-06-27 2011-06-28 Osamu Honmou Internally administered therapeutic agents for cranial nerve diseases comprising mesenchymal cells as an active ingredient
WO2015174087A1 (ja) * 2014-05-16 2015-11-19 公益財団法人先端医療振興財団 脳梗塞の予防及び／又は治療の為の医薬
JP2016506954A (ja) * 2013-02-06 2016-03-07 Ｎｃメディカルリサーチ株式会社 神経変性の治療のための細胞療法

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6653134B2 (en) * 1995-03-28 2003-11-25 Cp Hahnemann University Isolated stromal cells for use in the treatment of diseases of the central nervous system
US20050169896A1 (en) * 1999-05-14 2005-08-04 Henry Ford Health System Bone marrow transplantation for treatment of stroke
US8017112B2 (en) 1999-05-14 2011-09-13 Henry Ford Health System Transplantation of bone marrow stromal cells for treatment of neurodegenerative diseases
US6749850B1 (en) 1999-08-18 2004-06-15 The General Hospital Corporation Methods, compositions and kits for promoting recovery from damage to the central nervous system
CA2380953A1 (en) * 1999-08-18 2001-02-22 The General Hospital Corporation Methods, compositions and kits for promoting recovery from damage to the central nervous system
WO2001075094A1 (en) * 2000-04-04 2001-10-11 Thomas Jefferson University Application of myeloid-origin cells to the nervous system
KR100947577B1 (ko) * 2000-06-26 2010-03-15 엔씨 메디컬 리서치 가부시키가이샤 신경계 세포로 분화할 수 있는 세포를 포함하는 세포분획
ES2180433B1 (es) * 2001-05-28 2004-05-16 Universidad Miguel Hernandez De Elche. Empleo de celulas madre hematopoyeticas en la generacion de celulas madre neurales.
US9969980B2 (en) 2001-09-21 2018-05-15 Garnet Biotherapeutics Cell populations which co-express CD49c and CD90
EP1452586B1 (en) * 2001-10-30 2012-05-30 Nc Medical Research Inc. Method of inducing differentiation of mesodermal stem cells into nervous system cells
CN1638775A (zh) * 2002-01-04 2005-07-13 亨利福尔德健康组织 治疗疾病和损伤用的氧化氮供体
CA2474141A1 (en) 2002-01-14 2003-07-24 The Board Of Trustees Of The University Of Illinois Novel mammalian multipotent stem cells and compositions, methods of preparation and methods of administration thereof
US9969977B2 (en) 2002-09-20 2018-05-15 Garnet Biotherapeutics Cell populations which co-express CD49c and CD90
RU2283121C2 (ru) * 2004-11-29 2006-09-10 Государственное учреждение Научно-исследовательский институт клинической иммунологии СО РАМН Способ лечения инсульта
AU2008266885A1 (en) 2007-06-15 2008-12-24 Garnet Biotherapeutics Inc. Treatment of diseases and disorders using self-renewing colony forming cells cultured and expanded in vitro
CN105814196A (zh) * 2013-10-14 2016-07-27 哈达斯特医疗研究服务和开发有限公司 终末分化的神经元谱系的获得方法及其用途
RU2612981C1 (ru) * 2015-12-21 2017-03-14 Алексей Сергеевич Бывальцев Способ лечения ишемического инсульта
US11464804B1 (en) 2017-11-15 2022-10-11 Enrico Stazzone Intrathecal multifactorial infusion of heterogeneous autologous cell therapy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) * 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) * 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) * 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) * 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5612211A (en) * 1990-06-08 1997-03-18 New York University Stimulation, production and culturing of hematopoietic progenitor cells by fibroblast growth factors
US5750376A (en) * 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
US5851832A (en) * 1991-07-08 1998-12-22 Neurospheres, Ltd. In vitro growth and proliferation of multipotent neural stem cells and their progeny
AU690548B2 (en) * 1993-04-13 1998-04-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Use of neuro-derived fetal cell lines for transplantation therapy
US6653134B2 (en) * 1995-03-28 2003-11-25 Cp Hahnemann University Isolated stromal cells for use in the treatment of diseases of the central nervous system
EP1096941B1 (en) * 1998-05-07 2005-08-10 University Of South Florida Bone marrow cells as a source of neurons for brain and spinal cord repair
GB9904281D0 (en) * 1999-02-24 1999-04-21 Reneuron Ltd Transplantation

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005007176A1 (ja) * 2003-06-27 2005-01-27 Renomedix Institute Inc. 間葉系細胞を有効成分とする体内投与用脳神経疾患治療薬
JPWO2005007176A1 (ja) * 2003-06-27 2006-08-31 株式会社レノメディクス研究所 間葉系細胞を有効成分とする体内投与用脳神経疾患治療薬
US7968088B2 (en) 2003-06-27 2011-06-28 Osamu Honmou Internally administered therapeutic agents for cranial nerve diseases comprising mesenchymal cells as an active ingredient
JP2008063323A (ja) * 2006-09-06 2008-03-21 Henrich Cheng 損傷神経修復のためのフィブリン接着組成物およびその方法
JP2009067685A (ja) * 2007-09-10 2009-04-02 St Marianna Univ School Of Medicine 中枢神経再生剤
JP2011513318A (ja) * 2008-02-28 2011-04-28 ヘンリ フオルド ヘルス システム 中枢神経系損傷の治療を強化するために間質細胞を使用する組成物及び方法
JP2016506954A (ja) * 2013-02-06 2016-03-07 Ｎｃメディカルリサーチ株式会社 神経変性の治療のための細胞療法
WO2015174087A1 (ja) * 2014-05-16 2015-11-19 公益財団法人先端医療振興財団 脳梗塞の予防及び／又は治療の為の医薬

Also Published As

Publication number Publication date
PT1183035E (pt) 2015-03-04
CA2373808A1 (en) 2000-11-23
EP1183035A1 (en) 2002-03-06
DK1183035T3 (en) 2015-03-09
AU780994B2 (en) 2005-04-28
AU5130000A (en) 2000-12-05
WO2000069448A1 (en) 2000-11-23
ES2531592T3 (es) 2015-03-17
EP1183035A4 (en) 2003-05-07
US20090162327A1 (en) 2009-06-25
CA2373808C (en) 2011-04-19
EP1183035B1 (en) 2014-12-03

Similar Documents

Publication Publication Date Title
JP2002544234A (ja) 発作の処置のための骨髄移植
US20240226174A1 (en) Methods and compositions for provision of angiogenic factors
Gutiérrez-Fernández et al. Effects of intravenous administration of allogenic bone marrow-and adipose tissue-derived mesenchymal stem cells on functional recovery and brain repair markers in experimental ischemic stroke
Chen et al. Intracerebral transplantation of bone marrow with BDNF after MCAo in rat
US8337833B2 (en) Methods of improving central nervous system functioning
US20050169896A1 (en) Bone marrow transplantation for treatment of stroke
US8940293B2 (en) Transplantation of bone marrow stromal cells for treatment of neurodegenerative diseases
Dziewczapolski et al. Survival and differentiation of adult rat-derived neural progenitor cells transplanted to the striatum of hemiparkinsonian rats
HK1256610A1 (zh) 用於治療白質中風的幹細胞衍生的少突膠質細胞祖細胞
Cruz-Martinez et al. Intraventricular injections of mesenchymal stem cells activate endogenous functional remyelination in a chronic demyelinating murine model
Braccioli et al. delayed administration of neural stem cells after hypoxia–ischemia reduces sensorimotor deficits, cerebral lesion size, and neuroinflammation in neonatal mice
Hamedi et al. Intravenous transplantation of adipose-derived mesenchymal stem cells promoted the production of dopaminergic neurons and improved spatial memory in a rat model of Parkinson’s disease
WO2011043844A1 (en) Compositions of stem cells and stem cell factors and methods for their use and manufacture
US20080075698A1 (en) Brain-Localizing Bone Marrow Progenitor cells
AU2002225864A1 (en) Methods of improving central nervous system functioning
DE60123937T2 (de) Behandlung von neuro-degenerativen gastrointestinalkrankheiten durch impantation von neuronalen stammzellen und/oder deren nachkommen in gastrointestinalorgane
US20100119493A1 (en) Telencephalic Glial-Restricted Cell Populations and Related Compositions and Methods
EP3355898B1 (en) Induced pluripotent stem cell derived glial enriched progenitor cells for the treatment of white matter stroke
US20220241345A1 (en) Induced pluripotent stem cell derived glial enriched progenitor cells for the treatment of white matter stroke
RU2283121C2 (ru) Способ лечения инсульта
JP2018111722A (ja) 脳梗塞治療のための多能性幹細胞
US8452408B1 (en) Promotion of brain self-repair mechanisms by stereotaxic micro-stimulation
Shulman et al. Application of autologous peripheral blood mononuclear cells into the area of spinal cord injury in a subacute period: a pilot study in pigs
TWI363632B (en) A kit for treating brain tissue damage
Wilkinson et al. Cell Sources for CNSTE

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070320

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071005

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100122

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100412

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100421

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20100722

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110214